Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Perspective Therapeutics Reports 44% Confirmed Response Rate And 87.5% Progression-Free Patients Treated With [212Pb]VMT-α-NET At ESMO Congress 2025

Author: Benzinga Newsdesk | October 20, 2025 03:34am

Updated interim results with an additional ~19 weeks of follow-up since the prior update
[212Pb]VMT-α-NET continues to be well-tolerated
Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on study
Initial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026
Perspective will hold a conference call on Monday, October 20, 2025 at 8:30 am ET

Posted In: CATX